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The pharmacokinetics of 400 mg of ciprofloxacin given intravenously (i.v.) every 8 h (q8h) in severely septic
adults was documented in a multidisciplinary, tertiary referral intensive care unit (ICU). Sixteen evaluable
patients (three pharmacokinetic profiles) without renal dysfunction and with severe sepsis were studied. Cip-
rofloxacin at a dosage of 400 mg given i.v. q8h was administered over 1 h. Plasma samples for assay (high-
pressure liquid chromatography) were taken at timed intervals (preinfusion, at the end of infusion, and at 1,
2, 3, 5, and 7 h postinfusion) for first-dose kinetics (day 0 [D0]), D2, and between D6 and D8. All pharmaco-
kinetic variables were calculated by noncompartmental methods. Standard intensive care was provided. Peak
ciprofloxacin concentrations were as follows: D0, 6.01 6 1.93 mg/liter; D2, 6.68 6 2.01 mg/liter; and D6 to D8
6.45 6 1.54 mg/liter. Trough levels were as follows: D0, 0.6 6 0.5 mg/liter; D2, 0.7 6 0.4 mg/liter; and D6 to
D8 0.6 6 0.4 mg/liter. The areas under the concentration curves (8 h) were as follows: D0, 13.3 6 3.8 mg z
h/liter; D2, 16.8 6 5.4 mg z h/liter; and D6 to D8, 15.5 6 4.7 mg z h/liter. No drug-related serious adverse events
occurred. For 17 of 18 patients enrolled in the study, the causative organisms were susceptible to ciprofloxacin.
One patient developed renal failure (non-drug related) after the administration of three doses of ciprofloxacin.
One patient was infected with ciprofloxacin-resistant organisms on enrollment. Nine of 16 evaluable patients
had clinical cures, and 8 had bacteriological cures. One patient developed a ciprofloxacin-resistant superin-
fection. In two patients the clinical course was indeterminate. Two bacteriological failures occurred. We con-
clude that in critically ill adults ciprofloxacin at a dosage of 400 mg given i.v. q8h is safe. Its pharmacokinetic
profile provides bactericidal activity against most organisms encountered in an ICU. Except for some initial
accumulation on D2, no further accumulation occurred in patients without renal failure. Ciprofloxacin should
be administered i.v. at a dosage of 400 mg q8h for severe sepsis.
Ciprofloxacin is a fluoroquinolone with markedly increased
activity over those of other members of its class, such as nali-
dixic acid and norfloxacin. The compound is active against a
wide variety of gram-negative organisms as well as many gram-
positive organisms, with MICs generally in the range of 0.01 to
2.0 mg/liter (5). It should therefore be ideal for use against
many nosocomial infections.
The initial enthusiasm and excitement over the use of cip-
rofloxacin in the management of severe infections (particularly
nosocomial infections) have been tempered by reports of clin-
ical failure (15, 18).
Original registration data for ciprofloxacin were for the use
of oral dosages of 500 mg twice daily (b.i.d.) or, for severe
infections, 750 mg b.i.d. Initial registration data for intrave-
nous (i.v.) use were for the use of 200 mg b.i.d., with prob-
lems stressed much later (8). Data suggest that the area under
the plasma concentration-time curve (AUC) for 750 mg given
orally b.i.d. is similar to that for 400 mg given three times daily
i.v. (25).
Initial data (8), confirmed more recently (3, 4, 12, 19, 22),
have indicated the development of resistance to ciprofloxacin if
the drug is used at inappropriately low doses.
The limited pharmacokinetic data for 400 mg given to vol-
unteers i.v. every 8 h (q8h) have been encouraging, with ade-
quate AUCs being achieved (25, 26).
For i.v. use, particularly in severe infections or when the
MICs for the organisms may be high, e.g., in intensive care
units, it would seem that 400 mg q8h may be the better dosing
option.
Aim. Because there is a paucity of clinical studies with a
dosage of 1,200 mg/day (10, 11) we studied the pharmacoki-
netics of ciprofloxacin given by i.v. injection at a dosage of 400
mg q8h in critically ill patients who had severe sepsis.
MATERIALS AND METHODS
Clinical setting. Baragwanath Hospital is a 3,000-bed university and tertiary
referral hospital in Soweto, South Africa. The intensive care unit is a 24-bed
multidisciplinary unit that admits almost 1,000 patients per year and that runs at
about a 95% bed occupancy rate.
Institutional Review Board and University Ethics Committee approval was
obtained. When the trial started, a dose of 400 mg was not registered for use in
South Africa, and thus, South African Medicines Control Council approval was
also obtained.
Study design. We conducted a consecutive open-label study.
Study patients. Critically ill patients in the intensive care unit with nosocomial
infections (nosocomial severe sepsis) who needed antibiotics and from whom
informed consent could be obtained were given ciprofloxacin i.v. at a dosage of
400 mg q8h by continuous infusion over 1 h. Patients with diagnosed intra-
abdominal sepsis were part of another trial being performed concomitantly and
so they were not enrolled in the trial described here.
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(i) Severe sepsis. For the purpose of this study, the ACCP-SCCM Consensus
Conference definitions for sepsis, severe sepsis, and organ failure were used (1).
In brief, sepsis was defined as (i) clinical evidence of an infection (a primary site,
other than intra-abdominal, or radiologic studies which revealed potentially
infected material) (ii) plus at least two of the following: fever (rectal or core;
.38.3 or ,35.6°C), tachycardia (.90 beats/min), respiratory rate of .20 breaths/
min while spontaneously breathing or mechanically ventilated due to primary
pulmonary disease, or a leukocyte count of .12,000 cells/mm3, ,4,000 cells/mm3, or
.10% immature (band) forms. Severe sepsis was defined as sepsis associated
with organ dysfunction, hypoperfusion abnormality, or sepsis-induced hypoten-
sion.
(ii) Exclusion criteria. Patients were excluded from the study if their age was
,18 years; if they had a history of allergy to ciprofloxacin, other quinolone
derivatives, or metronidazole; if they had renal insufficiency with a creatinine
clearance (CLCR) of ,30 ml/min or were on hemodialysis (we do not perform
peritoneal dialysis); if they were pregnant or nursing or if the possibility of
pregnancy could not be excluded, if they were taking drugs which have a signif-
icant influence on liver enzyme induction, i.e., benzodiazepines, barbiturates,
phenytoin, rifampin, and isoniazid; or if they were taking drugs which have a
significant influence on liver enzyme inhibition, i.e., theophylline and cimetidine.
(iii) Evaluable patients. For study purposes, patients needed to have received
ciprofloxacin for a minimum period of 7 days (day 0 [D0] to D6) and to have had
three pharmacokinetic profiles done (first dose [D0], D2, and between D6 and
D8). If clinically indicated, the drug could be continued for up to 14 days.
Specimen collection. The pharmacokinetic profiles of ciprofloxacin in plasma
were obtained for the first dose (D0), D2, and between D6 and D8. For each
profile arterial blood was collected just before the administration of the antibi-
otic (time zero [T0]). Four hundred milligrams of ciprofloxacin was then infused
i.v. via a dedicated i.v. line over 1 h. Arterial blood samples taken after a half
hour (T0.5) and at T1 (just before the end of infusion), T2 (2 h after the start of
infusion), T3, T4, T6, and T8 (just before administration of the next dose). Blood
was placed into ammonium heparinized tubes, the tubes were immediately cen-
trifuged at room temperature for 2 min, and the plasma was separated. The
plasma was then stored at 220°C until analysis.
Ciprofloxacin assay. The concentrations of ciprofloxacin in plasma were de-
termined by high-pressure liquid chromatography with fluorescence detection by
using on-column focusing. Reversed-phase chromatography with gradient elu-
tion and fluorescence detection was applied to quantify the analytes by the
external standard procedure. Plasma samples were prepared by dilution involv-
ing a protein precipitation step for plasma with an acetonitrile buffer mixture.
Four hundred microliters of plasma was diluted with 400 ml of sample solvent; for
concentrations above 2 mg/liter, 200 ml of plasma was diluted with 800 ml of
sample solvent. The assay was linear over the range of 0.01 to 2 mg/liter. The
concentrations for the quality control samples ranged between 0.01 and 2.0
mg/liter. The intra- and interassays coefficient of variation, determined with
quality control samples, ranged from 2.4 to 8.4%.
Pharmacokinetic analysis. Mean and individual plasma ciprofloxacin concen-
trations were tabulated with relevant descriptive statistics. The mean and indi-
vidual concentration-time profiles were also plotted. The following pharmacoki-
netic variables were calculated from the concentrations in plasma. In the present
study the peak concentration (Cmax) was the concentration at the end of the
infusion period and the trough concentration (Cmin) was the concentration 8 h
after the start of the infusion. The terminal half-life (t1/2) was calculated from the
adjustment of a triple-exponential-function (C1e2z1t 2 C2e2z2t 1 C3e2z3t) plas-
ma concentration-versus-time profile. Here C1, C2, and C3 are concentrations at
three different times; z1, z2, and z3 are the rate constants; and t is time. The
regressions were done by the method of weighing nonlinear least squares with
weights that are inversely proportional to the concentrations. The t1/2 was then
calculated as t1/2 5 (ln 2)/z3. The AUC from time zero to infinity (AUC0–`) for
D0 and the AUC during the dosing interval for D2 and D6 to D8 (AUCt,SS) were
calculated according to the linear trapezoidal rule from 0 h to the last quantifi-
able concentration after drug administration. AUCt,SS was extrapolated to infin-
ity by adding Clast/z, where Clast is the final concentration measured. Total body
clearance (CL) was calculated as CL 5 dose/AUC, and the apparent volume of
distribution (V) was calculated as V 5 CL 3 MRT, where MRT is the mean
residence time. MRT was calculated by the equation MRT 5 AUMC0–`/AUC,
where AUMC0–` is the area under the first statistical moment curve from time
zero to infinity. The AUC/MIC ratio was calculated as the AUC over 24 h
divided by the MIC. The AUC over 24 h was calculated as the AUC over the 8-h
dosing interval multiplied by 3.
The accumulation ratios were calculated by the equation AUC0–8SS/AUC0–8dose 1,
where AUC0–8SS is the AUC from time zero to 8 h at steady state and AUC0–8dose 1
is the AUC from time zero to 8 h after administration of the first dose.
Statistical analysis. Descriptive and summary statistics were used. Variables
on D0 (see Table 2) were compared to variables on D2 and D6 to D8 by Stu-
dent’s t test.
Concomitant antimicrobial therapy. If it was thought to be clinically applica-
ble (with or without microbiological confirmation), vancomycin was added for
the treatment of enterococcal coinfection. Similarly, if anaerobic organisms were
suspected or isolated, metronidazole was used. Amphotericin B was added to the
therapy if fungi were suspected or isolated.
Other concomitant therapy. Standard intensive care techniques were used,
and full supportive therapy was provided to all patients as needed.
Clinical and microbiological evaluations. (i) Criteria for evaluation of clinical
response. Patients were evaluated at the conclusion of therapy as follows. (i)
Cure was the disappearance of all signs and symptoms related to the infection.
(ii) Improvement was a marked or moderate reduction in the severity and/or
number of signs and symptoms of infection. (iii) An indeterminate response was
an insufficient lessening of the signs and symptoms of infection to qualify as
improvement. (iv) Failure was the complete failure of treatment.
(ii) Criteria for evaluation of bacteriological response. Cure (bacteriological
response) for this study was defined when a culture of a clinical sample became
negative and remained negative upon continued culturing. Cure was presumed if
repeat samples for culture were not obtained due to the absence of material for
culture for a patient who had responded to therapy. Failure was defined as the
lack of eradication of the original organism and clinical failure as a result of
infection with the original organism. Superinfection was deemed to have oc-
curred if during or immediately after the end of therapy there was growth of a
new organism that was judged to be causing an infectious process. Secondary
infections were infections occurring after the trial.
Bacterial isolates were identified by genus and, usually, species. Susceptibility
to relevant antibiotics was tested by the disc diffusion and/or the broth or agar
dilution technique according to standards of the National Committee for Clinical
Laboratory Standards (17) in tests with American Type Culture Collection con-
trol strains. The MICs of ciprofloxacin were obtained.
RESULTS
To obtain 16 evaluable patients, 18 critically ill patients were
enrolled in the study. Their ages ranged from 18 to 54 years.
Their Apache II scores on the day of enrollment ranged from
5 to 23, with a mean of 14 (Table 1).
The relevant pharmacokinetics are presented in Table 2.
Figure 1a, b, and c display the plasma ciprofloxacin concen-
trations for D0, D2, and D6 to D8, respectively.
At least one organism susceptible to ciprofloxacin, assessed
to be the possible pathogen and therefore to be the causative
agent, was isolated from 17 of the 18 patients (Table 1). Twelve
patients were assessed to have demonstrated infections and 6
had suspected infections (27).
One patient was enrolled in the study and was subsequently
found to have a polymicrobial infection including infection
with gram-negative organisms resistant to ciprofloxacin (the
patient had a gunshot wound to the chest, paraplegia, and
empyema) and so was technically regarded as a dropout. One
patient developed renal failure after receipt of the third dose
of ciprofloxacin (assessed as non-drug related) and soon after
that died of multiple organ failure from overwhelming sepsis.
Four other patients died after the trial was completed.
No drug-related serious adverse events were directly attrib-
utable to ciprofloxacin. Some adverse events which may have
occurred were attributed to either the drugs that were used
concomitantly or the intrinsic disease process and its severity.
One patient had a generalized seizure while still on ciprofloxa-
cin subsequent to the D6 to D8 pharmacokinetic profile. Al-
though this could have been related to ciprofloxacin, it could
just as likely have been due to withdrawal from benzodiaz-
epine, the drug used to sedate the patient while the patient was
on a ventilator. All other adverse events that were noted dur-
ing the trial were assessed to be unrelated to ciprofloxacin and
were assessed to be related to the patients’ underlying disease
profiles (e.g., hemodynamic compromise, severe hypoxemia,
and tension pneumothorax).
The clinical and microbiological data are summarized in Ta-
ble 1. Of the 16 evaluable patients, 9 had clinical cures and 8
had bacteriological cures (no causative organism was isolated
from 1 patient). While on ciprofloxacin one patient developed
a superinfection with an Acinetobacter isolate resistant to cip-
rofloxacin. For two patients assessment of antibiotic therapy
was impossible because there was inadequate source control (in-
adequate abscess drainage or persistent drainage of pus from
the infected site). In two patients, organisms (both Acinetobac-
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ter isolates; one in blood and one in sputum) resistant to cip-
rofloxacin were isolated ab initio. The clinical course for these
two patients was indeterminate, i.e., they were assessed neither
to improve nor deteriorate while on ciprofloxacin. There were
two antibiotic (bacteriological) failures due to the apparent
emergence of resistance; i.e., two patients had an unresponsive
clinical course while they were on ciprofloxacin and newly
ciprofloxacin-resistant organisms were isolated.
Four patients developed secondary infections after receiving
ciprofloxacin and needed another course of antibiotics; only
one of the four patients eventually recovered.
DISCUSSION
By means of in vitro testing it has been shown that beta-
lactam antibiotics eradicate organisms by a slow continuous
killing characteristic. For this group of antibiotics it is the ac-
tual time that the antibiotic concentration is maintained above
the MIC for the organisms that is all important (2, 9, 23, 28).
Beta-lactam antibiotics have no postantibiotic effect (PAE)
(16, 28). This is in contrast to the aminoglycosides, which have
a dose-dependent killing characteristic with a significant PAE
(16). Fluoroquinolones in general have killing characteristics
that differ from those of both these classes of antibiotics. They
have a dose-dependent killing initially and then a slower killing
curve (4, 5, 19) and also exhibit a PAE (4–7, 19).
Like many other antibiotics the optimal i.v. dose of cipro-
floxacin is unknown (8). Various theoretical suggestions for op-
timal dosing regimens have been put forward.
High peak concentrations in plasma/MIC ratios and AUC/
MIC ratios (area under the inhibitory curve cumulative over
24 h/MIC) of .100 to 150 have been suggested to be a guide
to better i.v. dosing (11, 13, 19–21).
From a theoretical point of view, then, for the quinolones, a
high Cmax would help in the killing of the organism, as would
the time above the MIC and the AUC. All of this integrated
into one is the AUC/MIC ratio. Any PAE of the quinolones
would be an added benefit to the killing characteristics. It has
been suggested that a Cmax of up to eight times the MIC would
be optimal (21). Our average Cmax was almost 6.4 mg/ml. In
relation to our data this would mean that our Cmax is eight
TABLE 1. Relevant clinical and microbiological data for all patients enrolled in the study
Patient
no.
Apache II
score
Infective
diagnosis
Bacteriological
outcome
Clinical
outcome Organism Site
a MIC
(mg/ml)
1 14 Nosocomial pneumonia Cure Cure Acinetobacter baumannii TA 0.25
Klebsiella species TA ,0.13
2 17 Nosocomial pneumonia Failure Failure Acinetobacter baumannii TA 0.50
3 17 Nosocomial pneumonia Dropped out Klebsiella species TA ,0.13
Acinetobacter baumannii TA .64
4 16 Sepsis (bacteremia) Resistant organism Acinetobacter baumannii BLD .64
5 16 Nosocomial pneumonia Cure Cure Serratia marcescens BLD ,0.13
Klebsiella species BLD ,0.13
Serratia marcescens TA ,0.13
6 5 Nosocomial pneumonia Cure Cure Enterococcus faecalis BLD 0.25
Klebsiella oxytoca TA ,0.13
Staphylococcus epidermidis TA ,0.13
7 12 Nosocomial pneumonia Cure Cure Acinetobacter baumannii BLD & TA ,0.13 & ,0.13
8 19 Nosocomial pneumonia Superinfection Pseudomonas aeruginosa TA ,0.13
Klebsiella species TA 1.00
9 13 Nosocomial pneumonia Cure Cure Staphylococcus aureus PF ,0.13
Viridans group streptococcus PF ,0.13
10 19 Nosocomial pneumonia Failure Failure Klebsiella species BLD & PF ,0.13 & 0.13
Pseudomonas aeruginosa PF 0.13
Staphylococcus aureus PF 0.13
11 23 Empyema Inadequate source control Streptococcus equinus BLD & ICD 4.00 & 1.00
Staphylococcus aureus TA 0.25
Klebsiella species TA 0.13
Klebsiella species ICD 0.13
Proteus mirabilis TA 0.13
Streptococcus milleri ICD 0.50
12 14 Nosocomial pneumonia Cure Cure Acinetobacter baumannii BLD 0.25
13 11 Soft tissue infection No organism Cure None None None
14 9 Nosocomial pneumonia Resistant organism Acinetobacter baumannii TA .64
15 15 Soft tissue infection Cure Cure Staphylococcus aureus BLD 0.25
16 11 Neck abscess Inadequate source control Proteus mirabilis Pus ,0.13
Streptococcus milleri Pus 0.25
Pseudomonas aeruginosa TA 0.50
17 8 Empyema Dropped out Enterococcus faecalis PF None
Acinetobacter baumannii PF None
18 13 Nosocomial pneumonia Cure Cure Acinetobacter baumannii TA 0.13
a TA, tracheal aspirate; BLD, blood; PF, pleural fluid; ICD, intercostal drain.
TABLE 2. Values of pharmacokinetic parameters for ciprofloxacin
given i.v. at 400 mg q8h for the treatment of severe sepsisa
Day Cmax(mg/liter)
Cmin
(mg/liter)
t1/2
(h)
CL
(liter/h/
kg)
V
(liters/
kg)
AUC0–8
(mg z h/
liter)
0 (n 5 18) 6.01 (1.93) 0.6 (0.5) 3.9 (1.7) 0.4 (0.2) 1.4 (0.3) 13.3 (3.8)
2 (n 5 17) 6.68 (2.01) 0.7 (0.4) 3.2 (0.9) 0.4 (0.2) 1.2 (0.3) 16.8 (5.4)
6–8 (n 5 16) 6.45 (1.54) 0.6 (0.4) 3.3 (2.0) 0.4 (0.1) 1.3 (0.5) 15.5 (4.7)
a Values are given as means (SDs). There was no statistical significance be-
tween the groups (Student’s t test).
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times the MIC (0.8 mg/liter). Another suggestion for optimal
dosing is an AUC/MIC ratio of .100 to 150 (11, 13, 19–21).
Our AUC/MIC ratio (Table 2; AUC [which is for a dose given
q8h] multiplied by 3/MIC) was above 100 for organisms for
which MICs were roughly below 0.5 mg/liter. The Cmin from
our data was above 0.5 mg/liter. This means that ciprofloxacin
was maintained above the MIC for most of the dosing period.
Our data therefore mean that the theoretical optimal dosing
criteria are almost met in most aspects, i.e., a high Cmax, a high
AUC/MIC ratio, and a long period of time above the MIC. All
of this was obtained with only one possible drug-related side
effect: a seizure in one patient. Any lower dose or longer du-
ration between doses would produce less optimal pharmaco-
kinetics. Higher doses may well produce more side effects be-
cause accumulation would almost certainly occur.
Although our MIC data presented here are thorough (Table
1), the numbers in the study are too small to comment solely
on the bactericidal effect of AUC/MIC ratios. These data will
be part of a larger study to be reported later.
The accumulation ratios between D0 and D2 and D6 to D8
revealed some initial accumulation but no subsequent accumu-
lation. No accumulation was noted between D2 and D6 to D8.
Calculated accumulated ratios between D0 and D2 and D6 to
D8 were 1.3 (standard deviation [SD] 5 0.3) and 1.3 (SD 5
0.4), respectively. The ratio between D2 and D6 to D8 was 1
(SD 5 0.2). There were no statistical differences when com-
paring Cmin between the 3 study days (Table 2). We demon-
strated that, except initially, no further accumulation of cipro-
floxacin with our dosing regimen of 400 mg q8h occurred. This
is an important finding because it means that the frequency of
dosing in this dosing regimen cannot be regarded as being too
frequent.
These findings lead us to believe that the ideal i.v. dosage of
ciprofloxacin for the severely ill patient is 400 mg q8h. It pro-
vides a high Cmax, a high AUC/MIC ratio, and a long period of
time above the MIC, all without accumulation at the end of the
dosing interval. Any PAE that ciprofloxacin may exhibit would
be an added advantage to these characteristics.
We stress that none of our patients had renal failure, which
was an exclusion criterion for the trial, and if renal failure had
developed, the trial would have been discontinued for those
patients. Shah et al. (24) have shown that ciprofloxacin accu-
mulates in the presence of renal dysfunction. The dosage of
400 mg q8h should be decreased to every 12 h for patients with
CLCRs of between 31 and 60 ml/min/1.73 m
2 and should be
decreased further to a daily dose if CLCRs are less than 30
ml/min/1.73 m2.
Our data are the first that fully document the pharmacoki-
netics of and the clinical response to ciprofloxacin given i.v. at
a dosage of 400 mg q8h to critically ill patients, more particu-
larly, patients with severe sepsis. Fink et al. (10) reported good
clinical results in a study of severe pneumonia when they ad-
ministered 400 mg of ciprofloxacin q8h with imipenem at 1 g
q8h. They showed high clinical (69%) and bacteriological (also
69%) cure rates with ciprofloxacin, a finding in keeping with
our results. The low rate of side effects (1% seizures) in their
study was similar to that in our study. A dosage of 400 mg q8h
would therefore seem to be the preferred dose for the treat-
ment of severe infections. This has been suggested from in
vitro studies by Bauernfeind (4). Our clinical and bacteriolog-
ical results are in keeping with those of Fink et al. (10), al-
though it is difficult to compare the two studies, because the
design of our study was not similar to that of the study of Fink
et al. (10).
FIG. 1. Mean 6 SD plasma ciprofloxacin concentration versus time on D0 (a), D2 (b), and D6 to D8 (c).
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In a study with vancomycin, we have previously shown a
change in pharmacokinetic parameters between D2 and D7,
particularly in V and Cmax (14); hence, we determined the
pharmacokinetic profiles on D2 and D6 to D8 in this study. In
the present study we did not find such differences (Table 2).
The values of Cmax and t1/2 obtained in this study are com-
parable to the values obtained by Shah et al. (26) and Nix et al.
(20) in studies with healthy volunteers. CL and V, however,
were lower in our severely septic patients. Initially, the mean
CL for our patients was 84% of the CL reported for healthy
volunteers. In our patients the CL over the treatment course
remained relatively constant and was similar to that reported
at D5 for the healthy volunteers. The V for patients with severe
sepsis was 69% of that obtained for healthy subjects. We can-
not definitively explain this.
The ranges of the normalized CL (0.17 to 0.82 liter/h/kg) and
V (0.77 to 2.52 liters/kg) values were very wide, showing a
diversity in the septic critically ill patients. Further studies may
be necessary to accurately individualize ciprofloxacin dosing in
this patient population.
It is worth noting that our patient population is largely young
African patients without concomitant diseases. Their mean
Apache II scores of 14 (which are not their admission scores)
gives an indication that they were very ill and were often on a
ventilator and in respiratory failure. The severity of illness and
disease profiles for our patients are similar to those for the
patients in the study of Fink et al. (10), although the patient
populations may differ. It is thus feasible to extrapolate data
from these two studies into similar other intensive care unit
patients. Less sick patients, patients with smaller body struc-
tures, or patients who metabolize ciprofloxacin differently may
not necessarily need 1,200 mg/day.
Conclusion. Ciprofloxacin is safe when it is given to critically
ill adult patients i.v. at 400 mg q8h. This dosage produces ad-
equate Cmax/MIC ratios and results in adequate AUC/MIC ra-
tios, and concentrations in plasma are maintained above the
MIC for most of the dosing interval. This ensures bactericidal
activity against most organisms found in intensive care units. In
our patients, who did not have renal failure, there was no ac-
cumulation of ciprofloxacin. We conclude that 400 mg of cip-
rofloxacin given i.v. q8h should be the dose administered for
severe sepsis in the critically ill adult.
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